Venus Remedies Ltd

₹ 378 -2.78%

29 Nov - close price

venusremedies.com BSE: 526953 NSE : VENUSREM

About

Venus Remedies Ltd is an Indian Pharmaceutical company with a presence in domestic and international markets. It is primarily engaged in the business of pharmaceutical products manufacturing.^[1]

Key Points

Therapeutic Areas
The company manufactures and sells a very wide range of pharmaceutical products in therapeutic segments like Anti-infective (antibiotics), oncology, neurology, pain management, skin & wound care, anti-microbial resistance, etc.^[1]

Website BSE NSE

Market Cap ₹ 505 Cr.
Current Price ₹ 378
High / Low ₹ 407 / 145
Stock P/E 19.8
Book Value ₹ 352
Dividend Yield 0.00 %
ROCE 7.75 %
ROE 5.90 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company is almost debt free.
Stock is trading at 1.07 times its book value
Company has delivered good profit growth of 23.4% CAGR over last 5 years

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Company has a low return on equity of 8.67% over last 3 years.
Debtor days have increased from 31.9 to 50.7 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023
	126.07	121.94	111.37	129.81	202.56	124.34	142.45	143.08	139.89	117.08	155.64	95.15	167.72
	115.42	103.86	106.88	112.99	175.25	111.91	136.91	128.57	126.92	108.98	131.03	84.75	149.93
Operating Profit	10.65	18.08	4.49	16.82	27.31	12.43	5.54	14.51	12.97	8.10	24.61	10.40	17.79
OPM %	8.45%	14.83%	4.03%	12.96%	13.48%	10.00%	3.89%	10.14%	9.27%	6.92%	15.81%	10.93%	10.61%
	19.87	6.29	24.05	1.96	2.89	1.22	2.25	1.44	1.79	3.81	3.41	2.26	3.05
Interest	7.39	1.81	0.96	0.14	0.03	0.31	0.00	0.26	0.00	0.15	0.00	0.06	0.06
Depreciation	8.61	8.70	9.38	8.62	8.71	8.64	7.56	7.80	8.99	7.22	8.29	7.55	6.44
Profit before tax	14.52	13.86	18.20	10.02	21.46	4.70	0.23	7.89	5.77	4.54	19.73	5.05	14.34
Tax %	10.26%	15.95%	-92.91%	-16.77%	-7.88%	-20.21%	0.00%	12.67%	7.63%	27.53%	43.94%	76.63%	30.68%
	13.03	11.66	35.11	11.70	23.15	5.65	0.23	6.89	5.33	3.29	11.06	1.18	9.94
EPS in Rs	10.56	9.45	28.45	8.75	17.32	4.23	0.17	5.15	3.99	2.46	8.27	0.88	7.44
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
	401	459	531	455	407	400	372	322	335	544	597	552	536
	298	339	393	366	326	349	333	289	295	490	535	492	475
Operating Profit	103	120	138	89	81	51	39	33	41	54	62	60	61
OPM %	26%	26%	26%	20%	20%	13%	11%	10%	12%	10%	10%	11%	11%
	0	0	0	1	2	2	2	-3	-4	43	8	10	13
Interest	27	25	29	41	38	34	35	25	13	13	0	0	0
Depreciation	25	33	40	46	42	40	34	34	32	35	34	32	30
Profit before tax	51	63	69	3	4	-22	-28	-30	-8	49	36	38	44
Tax %	7%	9%	7%	-95%	52%	21%	-11%	4%	-24%	-27%	-12%	30%
	47	57	64	5	2	-17	-31	-29	-10	62	41	27	25
EPS in Rs	48.33	54.36	56.20	4.51	1.49	-13.84	-24.87	-23.15	-8.10	50.05	30.46	19.88	19.05
Dividend Payout %	6%	6%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	2%
5 Years:	8%
3 Years:	18%
TTM:	-3%

Compounded Profit Growth
10 Years:	-7%
5 Years:	23%
3 Years:	119%
TTM:	41%

Stock Price CAGR
10 Years:	6%
5 Years:	50%
3 Years:	39%
1 Year:	89%

Return on Equity
10 Years:	3%
5 Years:	4%
3 Years:	9%
Last Year:	6%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Sep 2023
Equity Capital	10	11	11	11	11	12	12	12	12	12	13	13	13
Reserves	289	364	450	445	426	376	350	320	311	374	427	447	458
	220	271	289	321	335	312	307	298	220	51	43	42	42
	55	72	84	64	70	65	82	102	100	118	97	98	128
Total Liabilities	574	718	834	841	843	765	751	733	644	556	580	601	640
	355	401	439	444	452	406	389	364	289	262	241	216	204
CWIP	23	48	68	78	80	66	65	65	25	25	25	26	26
Investments	0	0	0	0	0	0	0	0	0	0	0	20	3
	196	268	327	319	310	293	297	304	330	269	314	339	407
Total Assets	574	718	834	841	843	765	751	733	644	556	580	601	640

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
	42	52	53	68	47	59	31	45	78	132	41	37
	-95	-104	-95	-67	3	-18	8	-11	-5	57	-17	-58
	53	55	40	-1	-46	-44	-39	-35	-73	-162	-9	-1
Net Cash Flow	-0	3	-2	-1	3	-4	0	-1	-0	27	14	-22

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Debtor Days	36	37	45	51	55	43	46	43	33	21	24	51
Inventory Days	156	178	173	194	219	226	246	286	296	129	118	132
Days Payable	20	26	38	40	38	48	52	72	77	76	47	56
Cash Conversion Cycle	173	190	180	204	236	221	240	257	252	74	95	127
Working Capital Days	88	98	115	146	179	163	144	127	166	74	85	112
ROCE %	17%	15%	14%	6%	5%	2%	1%	1%	2%	8%	8%	8%

Shareholding Pattern

Numbers in percentages

2 Recently

	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023
	35.89%	35.89%	40.81%	40.81%	40.81%	40.81%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%
	0.04%	0.04%	0.02%	0.10%	0.28%	0.33%	0.96%	1.13%	1.07%	1.00%	0.98%	1.03%
	64.07%	64.07%	59.17%	59.09%	58.91%	58.86%	57.28%	57.11%	57.19%	57.26%	57.26%	57.21%
No. of Shareholders	14,751	13,829	14,419	16,617	18,231	19,952	21,189	22,015	22,243	21,719	20,498	19,267

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Sep 2023
	37.51%	37.51%	37.51%	35.89%	35.89%	40.81%	41.76%	41.76%
	0.48%	0.48%	0.04%	0.04%	0.04%	0.33%	1.00%	1.03%
	0.28%	0.45%	0.02%	0.00%	0.00%	0.00%	0.00%	0.00%
	61.73%	61.56%	62.43%	64.07%	64.07%	58.86%	57.26%	57.21%
No. of Shareholders	20,556	19,316	18,375	17,209	13,829	19,952	21,719	19,267

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Venus Remedies Ltd

Venus Remedies Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings